CureVac’s flu vaccine to undergo ‘targeted optimisation’ for certain strains

04 Apr 2024
firstwordpharma.com
VaccineClinical ResultPhase 2mRNAImmunotherapy
CureVac reported a hit and a miss for its multivalent seasonal flu vaccine on Thursday. While the candidate, which is partnered with GSK, boosted antibody titers against influenza A strains, the immune responses fell short against the B strains.
The interim data was from the second part of a Phase I/II study that enrolled 480 healthy younger adults ages 18 to 64, and the same number of older adults ages 65 to 85. Participants received one of three different dose levels of CureVac’s vaccine, which was developed with the biotech’s second-generation mRNA backbone, and immune responses were compared with approved seasonal flu vaccines.
In both age groups, geometric mean antibody titers generated by the vaccine candidate against influenza A strains “numerically exceeded” titers of the comparator vaccines “across all tested dose levels.” However, against influenza B strains, titers were lower across age groups and doses.
According to the company, “targeted optimisations to further improve immune responses against influenza B strains will be tested in an additional Phase II study.”
"Results regarding influenza A strains were strong,” CureVac CEO Myriam Mendila said. “Immunogenicity for B strains was in line with our expectations also in view of other initial mRNA-based clinical flu development programs. We are confident that planned optimizations will improve performance against these historically challenging influenza strains."
The company said its vaccine candidate had an “acceptable” safety and tolerability profile, and the majority of reported adverse events were either grade 1 or grade 2 within a week of dosing.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
-
Indications
Targets
-
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.